Why in news?
A recent global cancer assessment has renewed attention to infections that can contribute to cancer, including Epstein–Barr virus. The International Agency for Research on Cancer, or IARC, released the assessment on 29 September. It estimated that infections accounted for about 2.3 million new cancer cases worldwide in 2024, roughly 12% of the total. That figure covers several infectious agents; it is not the burden caused by Epstein–Barr virus alone. The Hindu's 6 October explainer examined this widely encountered virus in that context. The central distinction is between an infection's ability to cause certain cancers and the much smaller likelihood of that outcome for an individual.
What the virus is and how it spreads
Epstein–Barr virus, usually shortened to EBV, belongs to the herpesvirus family. It is also known as human herpesvirus 4. Infection is common, and many people acquire it during childhood without a recognisable illness. Saliva is a major route of transmission, including through shared objects contaminated with saliva. In adolescents and adults, infection can cause infectious mononucleosis, an illness associated with fatigue, fever, sore throat and swollen glands.
The United States Centers for Disease Control and Prevention explains that the virus remains in the body after infection. It can enter a latent, or inactive, state and later reactivate. Reactivation does not always produce symptoms. People with weakened immune systems are more likely to develop problems from it. This is different from saying that everyone with past infection remains continuously ill or infectious in the same way.
How infection and cancer are connected
The United States National Cancer Institute identifies EBV as a cause of certain lymphomas and cancers of the nose and throat. A lymphoma is a cancer involving cells of the lymphatic system, which forms part of the body's immune defences. The institute also explains that infectious agents can interfere with controls on cell growth or weaken immune protection. These are biological pathways through which an infection can contribute to cancer, rather than an immediate transformation after exposure.
More than 90% of people worldwide are infected with EBV during their lifetime, according to the institute. Many never experience noticeable symptoms. That widespread exposure is important context for interpreting the cancer association. A positive history of infection does not establish that cancer is present, and it does not predict an inevitable future diagnosis. The scientific relationship is real, but the outcome depends on more than simply encountering the virus.
What a Group 1 classification means
EBV is classified as carcinogenic to humans in IARC's Group 1. This classification concerns the strength of evidence that an agent can cause cancer. It does not rank every exposed person's probability of developing cancer, or mean that all Group 1 agents carry equal risks. Hazard and individual risk are different questions. The first asks whether an agent can cause harm; the second concerns the likelihood under particular conditions of exposure and susceptibility.
The new global assessment estimates the contribution of infections across populations. Such estimates help identify the scale of preventable disease and the value of infection-control research. They are not individual diagnostic tests. Nor can the combined total for all cancer-related infections be assigned to one virus. Keeping the population estimate, causal evidence and individual clinical assessment separate prevents an alarming headline from becoming a misleading personal conclusion.
Why a blood-test result needs context
EBV antibody tests can help distinguish patterns consistent with recent or past infection. However, some antibodies persist long after the initial illness. The Centers for Disease Control and Prevention cautions that high antibody levels may remain for years and do not alone prove a recent infection. It also does not recommend the Monospot test for general use. Symptoms, timing and the particular test result must be interpreted together rather than reduced to a simple positive-versus-negative label.
Conclusion
EBV's widespread presence makes prevention and a better understanding of its long-term effects important research priorities. Current public-health guidance identifies no preventive EBV vaccine or specific treatment that eliminates the infection. Yet past exposure is not a cancer diagnosis, and most infections do not produce a recognisable illness. Population-level cancer research and individual clinical assessment serve different purposes; progress depends on understanding both without treating them as interchangeable.